Breaking News

Canada's Consumer Price Index Rises a Less-Than-Forecast 2% in November
Tweet TWEET

Enanta Pharmaceuticals Announces the Appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and General Counsel

  Enanta Pharmaceuticals Announces the Appointment of Nathaniel S. Gardiner,
  J.D. as Senior Vice President and General Counsel

Business Wire

WATERTOWN, Mass. -- May 12, 2014

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) a research and development-focused
biotechnology company dedicated to creating small molecule drugs in the
infectious disease field, today announced the appointment of Nathaniel S.
Gardiner, J.D. as Senior Vice President and General Counsel. Mr. Gardiner has
over 25 years of experience as outside general counsel advising private and
public biotechnology companies.

“After working with Nat for so many years as our outside counsel, we are
thrilled to have him join as a permanent member of senior management,”
commented Jay R. Luly, Ph.D.

Mr. Gardiner was previously a corporate and securities law partner for 25
years, starting at Palmer & Dodge LLP and continuing through its merger into
Edwards Angell Palmer & Dodge LLP, which is now known as Edwards Wildman
Palmer LLP. Since 2008 Mr. Gardiner had been co-chair of the firm’s Life
Sciences Group, and before that he was co-chair of the Business Law
Department. In his private practice, Mr. Gardiner was Enanta’s outside counsel
and Secretary since it was founded, and he led its IPO legal team. He also
serves as a Trustee of Joslin Diabetes Center, Inc. in Boston, where he is a
member of the Executive Committee and Chair of the Compensation Committee.

Mr. Gardiner received his A.B. from Harvard College and his J.D. from the
University of Virginia School of Law.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology
company that uses its robust chemistry-driven approach and drug discovery
capabilities to create small molecule drugs in the infectious disease field.
Enanta is discovering, and in some cases developing, novel inhibitors designed
for use against the hepatitis C virus (HCV). These inhibitors include members
of the direct acting antiviral (DAA) inhibitor classes – protease (partnered
with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as
well as a host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of antibiotics,
called Bicyclolides, for the treatment of multi-drug resistant bacteria, with
a focus on developing an intravenous and oral treatment for hospital and
community MRSA (methicillin-resistant Staphylococcus aureus) infections.

Contact:

Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
Media Contact
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
 
Press spacebar to pause and continue. Press esc to stop.